

Tamir Biotechnology, Inc.  
Form 10-Q  
May 07, 2013

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**For Quarterly Period Ended October 31, 2011**

**Or**

**£ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**Commission File Number 0-11088**

**TAMIR BIOTECHNOLGY, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

**22-2369085**

(State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.)

-

**5825 Oberlin Drive, San Diego, CA 92121**

Edgar Filing: Tamir Biotechnology, Inc. - Form 10-Q

(Address of principal executive offices, zip code)

Registrant's telephone number (including area code): (732) 823-1003

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES  NO  S

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  Accelerated Filer  Non-accelerated Filer  Smaller reporting company  S

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No  S

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

<b>Class</b>	<b>Outstanding at May 6, 2013</b>
Common Stock, \$.001 par value	217,364,331

**TAMIR BIOTECHNOLOGY, INC.**

**OCTOBER 31, 2011**

**(UNAUDITED)**

**INDEX**

	<b><u>Page</u></b>
PART I FINANCIAL INFORMATION	3
ITEM 1. FINANCIAL STATEMENTS:	3
Notes to Financial Statements	6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4. CONTROLS AND PROCEDURES	22
PART II OTHER INFORMATION	22
ITEM 1. LEGAL PROCEEDINGS	22
ITEM 1A. RISK FACTORS	23
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES	23
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	23
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS	23
ITEM 5. OTHER INFORMATION	23
ITEM 6. EXHIBITS	23
Signatures	24

**PART I - FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****Tamir Biotechnology, Inc.****Balance Sheets**

	October 31, 2011 (Unaudited)	July 31, 2011
<b>ASSETS</b>		
Current assets:		
Cash and equivalents	\$ 146,463	\$ 354,198
Prepaid expenses	35,758	45,106
Other assets	11,382	—
Total current assets	193,603	399,304
Property and equipment, net of accumulated depreciation of \$381,826 in October 31, 2011 and \$379,325 in July 31, 2011	5,425	7,926
Other assets	—	11,382
Deferred financing costs	82,184	102,901
<b>TOTAL ASSETS</b>	<b>\$281,212</b>	<b>\$521,513</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIENCY</b>		
Current liabilities:		
Accounts payable	\$560,189	\$530,373
Accrued expenses	532,602	608,401
Derivative liability	2,264,587	4,603,285
Convertible debt, less discount of \$1,071,461 (related party, \$321,438) at October 31, 2011	2,178,539	—
Accrued interest, convertible debt (related party, \$98,034) at October 31, 2011	326,781	—
Deferred rent	4,645	6,193
Total current liabilities	5,867,343	5,748,252
Other liabilities:		
Accounts payable, net of current portion	444,223	444,223

Edgar Filing: Tamir Biotechnology, Inc. - Form 10-Q

Accrued retirement benefits	231,250	231,250
Convertible debt, less discount of \$1,341,553 (related party, \$572,534) at July 31, 2011	—	1,908,447
Accrued interest, convertible debt ( related party, \$85,880) at July 31, 2011	—	286,268
Total other liabilities	675,473	2,870,188
<b>TOTAL LIABILITIES</b>	<b>6,542,816</b>	<b>8,618,440</b>
Commitments and Contingencies		
Stockholders' deficiency:		
Preferred stock, \$.001 par value. Authorized and unissued, 1,000,000 shares at October 31, 2011 and July 31, 2011	—	—
Common stock \$.001 par value. Authorized 250,000,000 shares at October 31, 2011 and July 31, 2011, issued and outstanding 49,823,880 shares at October 31, 2011, and July 31, 2011	49,824	49,824
Additional paid in capital	100,850,221	100,828,262
Accumulated deficit	(107,161,649)	(108,975,013)
Total stockholders' deficiency	(6,261,604 )	(8,096,927 )
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY</b>	<b>\$281,212</b>	<b>\$521,513</b>

The accompanying notes are an integral part of these financial statements.

**Tamir Biotechnology, Inc.****Statements of Operations**

(Unaudited)

	Three Months Ended October 31,	
	2011	2010
Revenues	\$—	\$—
Operating expenses:		
Research and development	70,571	219,326
General and administrative	122,937	409,770
Total operating expenses	193,508	629,096
Loss from operations	(193,508 )	(629,096 )
Other Income (Expense):		
Investment income	1	147
Amortization of debt discount	(270,091 )	(270,092 )
Change in fair value of derivative liability	2,338,698	(7,900,964 )
Interest expense - related party	(12,154 )	(12,155 )
Interest expense - other	(49,582 )	(50,035 )
Total other income (expense)	2,006,872	(8,233,099 )
Income (Loss) before income tax expenses	1,813,364	(8,862,195 )
Income tax expenses	—	—
Net Income (Loss)	\$1,813,364	\$(8,862,195 )
Income (Loss) per Common Shares		
Basic	\$0.04	\$(0.19 )
Diluted	\$0.00	\$(0.19 )
Weighted Average Number of Shares Outstanding		
Basic	49,823,880	47,317,576
Diluted	73,669,085	47,317,576

The accompanying notes are an integral part of these financial statements.



**Tamir Biotechnology, Inc.****Statements of Cash Flows**

(Unaudited)

	Three Months Ended	
	October 31,	
	2011	2010
Cash Flows From Operating Activities:		
Net Income (Loss)	\$1,813,364	\$(8,862,195)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation	2,501	11,784
Share-based compensation expense	21,959	92,995
Decrease in deferred rent	(1,548 )	(1,549 )
Amortization of debt discount	270,091	270,092
Fair value of derivative liability	(2,338,698)	7,900,964
Amortization of deferred financing costs	20,717	20,717
Changes in assets and liabilities:		
Decrease in prepaid expenses and other assets	9,348	36,445
Decrease in restricted cash	—	238,397
Increase in accounts payable	29,816	21,350
Decrease in accrued retirement benefits	—	(39,000 )
(Decrease) Increase in accrued expenses	(35,285 )	67,255
Net Cash Used In Operating Activities	(207,735 )	(242,745 )
Cash Flows From Financing Activities:		
Decrease in deferred financing costs	—	(3,027 )
Payment of capital lease obligation	—	(1,231 )
Proceeds from exercise of stock options and warrants, net	—	2,600
Net Cash Used in Financing Activities	—	(1,658 )
Net decrease in cash and equivalents	(207,735 )	(244,403 )
Cash and equivalents at beginning of period	354,198	321,253
Cash and equivalents at end of period	\$146,463	\$76,850
Supplemental Disclosure of Cash Flow Information		
Cash paid for interest	\$505	\$960
Cash paid for taxes	\$—	\$—

The accompanying notes are an integral part of these financial statements.





**TAMIR BIOTECHNOLOGY, INC.**

**NOTES TO FINANCIAL STATEMENTS**

**OCTOBER 31, 2011 (UNAUDITED) and JULY 31, 2011**

NOTE 1 - Business Description

Tamir Biotechnology, Inc. (formerly known as Alfacell Corporation) (“Tamir”, “Company”, “we”, “us”, “our”, “our company”, “our companies”) is a Delaware corporation incorporated on August 24, 1981. We are a biopharmaceutical company primarily engaged in the discovery, development, and licensing of a new class of antiviral therapeutic drugs for the treatment of pathological conditions. Our proprietary drug discovery and development program consists of novel therapeutics which are being developed from amphibian ribonucleases (RNases). Beginning in 2011, Tamir’s focus has been its antiviral therapeutic drug development strategy and plan.

The Company is engaged in the research, development, licensing and commercialization of drugs for the treatment of various forms life threatening diseases. As of October 31, 2011, the Company is pursuing various available strategic alternatives to raise additional funds. The Company plans to continue the further development of its drug product candidates, which requires substantial capital for research, product development, and market development activities. The Company has not yet initiated marketing of a commercial drug product. Future product development will require clinical testing, regulatory approval, and substantial additional investment prior to commercialization. The future success of the Company is dependent on its ability to make progress in the development of its drug product candidates and, ultimately, upon its ability to attain future profitable operations through the successful manufacturing and marketing of those drug product candidates. There can be no assurance that the Company will be able to obtain the necessary financing or regulatory approvals to be able to successfully develop, manufacture, and market its products, or attain successful future operations. Accordingly, the Company’s future success is uncertain.

The Company is no longer a development stage enterprise as it has started generating revenue from licensing, resulting from its past and ongoing research and development activities. Management expects to generate such revenue, as well as revenue from product sales, on an ongoing basis.

In addition, uncertainty exists as to the Company’s ability to protect its rights to patents and its proprietary information. There can also be no assurance that research and discoveries by others will not render some or all of the Company’s technology or drug product candidates noncompetitive or obsolete, nor can there be any assurance that unforeseen problems will not develop with the Company’s technologies or applications, or that the Company will be able to address successful technological challenges it encounters in its research and development programs. While the Company maintains insurance to cover the use of its drug product candidates in clinical trials, it does not maintain insurance covering the sale of its products nor is there any assurance that it will be able to obtain or maintain such insurance on acceptable terms or with adequate coverage against potential liabilities.

NOTE 2 - Summary of Significant Accounting Policies

*Going concern*

The accompanying financial statements were prepared assuming we will continue as a going concern. The Company had net income of \$1,813,364 and net loss of \$8,862,195 for the three months ended October 31, 2011 and 2010, respectively. As of October 31, 2011, the Company had a negative working capital of \$5,673,740 and an accumulated deficit of \$107,161,649. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue its existence. The recovery of the Company's assets is dependent upon continued operations of the Company and future events, the outcome of which is unknowable. The Company intends to continue to attempt to raise additional capital, but there can be no certainty that such efforts will be successful.

-6-

### *Use of Estimates*

The preparation of financial statements in conformity with United States generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.

### *Cash Equivalents*

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of these investments approximates their fair market value due to their short maturity and liquidity. The Company maintains cash deposits with banks that at times exceed applicable insurance limits.

### *Property and Equipment*

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not extend the life of assets are expensed when incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in operations for the period in which the transaction takes place.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount exceeds the fair value of the asset.

### *Derivative Instrument Liability*

The Company accounts for derivative instruments with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, “*Derivatives and Hedging*”, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged.

### *Accounting For Warrants Issued With Convertible Debt*

The Company accounts for the intrinsic value of beneficial conversion rights arising from the issuance of convertible debt instruments with non-detachable conversion rights that are in-the-money at the commitment date pursuant to the consensus of ASC 470-20 “*Debt: Debt With Conversion and Other Options*”. Such value is allocated to additional paid-in capital and the resulting debt discount is charged to interest expense over the terms of the notes payable. Such value is determined after first allocating an appropriate portion of the proceeds received to warrants or any other detachable instruments included in the exchange.



### *Fair Value Measurements*

The Company adopted ASC Topic 820, “*Fair Value Measurements*”, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

### *Income Taxes*

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Management provides valuation allowances against the deferred tax assets for amounts which are not considered “more likely than not” to be realized.

### *Revenue Recognition*

The Company recognizes revenue in accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, “*Revenue Recognition*” issued by the staff of the SEC. Under SAB No. 104, revenue is

recognized when persuasive evidence of an arrangement exists, delivery has occurred and/or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured.

-8-

The Company enters into marketing and distribution agreements, which contain multiple deliverables. Under the provisions of ASC 605, “*Revenue Recognition - Multiple Deliverable Revenue Arrangements*”, the Company evaluates whether these deliverables constitute separate units of accounting to which total arrangement consideration is allocated. A deliverable qualifies as a separate unit of accounting when the item delivered to the customer has standalone value, there is objective and reliable evidence of fair value of items that have not been delivered to the customer, and, if there is a general right of return for the items delivered to the customer, delivery or performance of the undelivered items is considered probable and substantially in the control of the Company. Arrangement consideration is allocated to units of accounting on a relative fair-value basis or the residual method if the Company is unable to determine the fair value of all deliverables in the arrangement. Consideration allocated to a unit of accounting is limited to the amount that is not contingent upon future performance by the Company. Upon determination of separate units of accounting and allocated consideration, the general criteria for revenue recognition are applied to each unit of accounting. Up-front nonrefundable fee received by the Company for substantive milestones are recognized upon achievement of the milestones. Any amounts received prior to satisfying our revenue recognition criteria are recorded as deferred in the accompanying balance sheets.

In July 2007, the Company entered into an agreement with USP to market, sell and distribute ONCONASE® in Poland and other countries in Eastern Europe. The Company received a \$0.1 million upfront nonrefundable fee in July 2007 and is entitled to receive future additional fees, milestone payments and royalties. USP is responsible for all commercial costs in the territory. The Company has agreed to provide or arrange for contract manufacture of a commercial supply of ONCONASE® upon receipt of marketing approval in the territory. The up-front nonrefundable fee received by the Company will be recognized ratably as revenue once the general criteria for revenue recognition has been met for the unit of accounting to which the fee has been allocated.

In January 2008, the Company entered into a marketing and distribution agreement with BL&H Co. Ltd. (“BL&H”) for the commercialization of ONCONASE® in Korea, Taiwan and Hong Kong. Under the agreement, the Company received a \$0.1 million up-front fee and is eligible to receive additional cash milestones and 50% of net sales in the territory. The Company will be responsible for the manufacture and supply of ONCONASE® to BL&H, while BL&H will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.

In January 2008, the Company entered into a US License Agreement for ONCONASE® with Par Pharmaceutical, Inc. (“Par”). Under the terms of the License Agreement, Strativa, the proprietary products division of Par, received exclusive marketing, sales and distribution rights to ONCONASE® for the treatment of cancer in the US and its territories. The Company retained all rights and obligations for product manufacturing, clinical development and obtaining regulatory approvals, as well as all rights for those non-US jurisdictions in which the Company has not currently granted any such rights or obligations to third parties. The Company received a nonrefundable cash payment of \$5 million upon the signing of the License Agreement and would have been entitled to additional development and sales milestone payments and double-digit royalties on net sales of ONCONASE®.

On September 8, 2009, the Company and Par entered into a Termination and Mutual Release Agreement (the “Termination Agreement”) pursuant to which the Company’s License Agreement and Supply Agreement with Par were terminated. The License Agreement was terminated and all rights under the license granted to Par revert back to the Company under the Termination Agreement. Under the Supply Agreement, the Company had agreed to supply all of Par’s requirements for ONCONASE®. Pursuant to the Termination Agreement, Par will be entitled to a royalty of 2% of net sales of ONCONASE® or any other ranpirinase product developed by the Company for use in the treatment of cancer in the U.S. and its territories commencing with the first sale of such product and terminating upon the later to occur of the 12<sup>th</sup> anniversary of the first sale and the date of expiration of the last valid claim of a pending application or issued patent owned or controlled by the Company with respect to such product.



The Company has evaluated both the License Agreement and the Termination Agreement and has determined that the Company is obligated to provide royalty payments in the event the Company has net sales in the field of cancer. In February 2011, we decided to suspend the Phase II trial of ONCONASE® in combination with carboplatinum regimens in patients suffering from non-small cell lung cancer who have reached maximum progression after receiving two cycles of Alimta plus Carboplatin. Given our limited resources and based upon previously reported positive *in vitro* antiviral results, we shifted our focus to the completion of *in vivo* studies for CMV and HPV. At this point we terminated any further development of our compounds in the cancer field. Therefore, as of February 2011, there was nothing left to do to earn the non-refundable deposit and the Company has taken the \$5 million as income.

-9-

### *Research and Development*

Research and development costs (“R&D”) are expensed as incurred. These costs include, among other things, consulting fees and costs related to the conduct of human clinical trials. The Company also allocates indirect costs, consisting primarily of operational costs for administering R&D activities to R&D expenses.

### *Share-Based Compensation*

The Company accounts for its share-based compensation in accordance with the provisions of ASC Topic 718, “*Compensation – Stock Compensation*”, which establishes accounting for equity instruments exchanged for employee services and ASC Subtopic 505-50, “*Equity-Based Payments to Non-Employees*”, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests.

The fair value of the stock options at the grant date was estimated using the Black-Scholes option pricing mode. The risk-free interest rate for periods approximating the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected stock price volatility is based on historical volatility of the Company’s stock price. For post July 31, 2005 grants, the expected term until exercise is derived using the “simplified” method as allowed under the provisions of the SEC’s SAB No. 110, “*Disclosures about Fair Value of Financial Instruments*” and represents the period of time that options granted are expected to be outstanding.

### *Leases*

With respect to our operating leases, the Company applies the provisions of the FASB “*Accounting for Leases*”, recognizing rent expense on a straight-line basis over the lease term due to escalating lease payments and landlord incentives.

### *Contingencies*

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Recoveries from other parties are recorded when realized.

### *Recently Issued Accounting Pronouncements*

In June 2011, FASB issued Accounting Standards Update (“ASU”) 2011-05, “*Comprehensive Income (Topic 220): Presentation of Comprehensive Income*,” which is effective for annual reporting periods beginning after December 15, 2011. ASU 2011-05 will become effective for the Company on January 1, 2012. This guidance eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. In addition, items of other comprehensive income that are reclassified to profit or loss are required to be presented separately on the face of the financial statements. This guidance is intended to increase the prominence of other comprehensive income in financial statements by requiring that such amounts be presented either in a single

continuous statement of income and comprehensive income or separately in consecutive statements of income and comprehensive income. The adoption of ASU 2011-05 is not expected to have a material impact on our financial position or results of operations.

-10-

In May 2011, the FASB issued ASU 2011-04, "*Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs*," which is effective for annual reporting periods beginning after December 15, 2011. This guidance amends certain accounting and disclosure requirements related to fair value measurements. Additional disclosure requirements in the update include: (1) for Level 3 fair value measurements, quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements to changes in the unobservable inputs; (2) for an entity's use of a nonfinancial asset that is different from the asset's highest and best use, the reason for the difference; (3) for financial instruments not measured at fair value but for which disclosure of fair value is required, the fair value hierarchy level in which the fair value measurements were determined; and (4) the disclosure of all transfers between Level 1 and Level 2 of the fair value hierarchy. ASU 2011-04 will become effective for the Company on January 1, 2012. The Company does not expect that the guidance effective in future periods will have a material impact on its financial statements.

In April 2011, the FASB issued ASU 2011-02, "*Receivables (Topic 310): A Creditor's Determination of Whether a Restructuring is a Troubled Debt Restructuring*." This amendment explains which modifications constitute troubled debt restructurings ("TDR"). Under the new guidance, the definition of a troubled debt restructuring remains essentially unchanged, and for a loan modification to be considered a TDR, certain basic criteria must still be met. For public companies, the new guidance is effective for interim and annual periods beginning on or after June 15, 2011, and applies retrospectively to restructuring occurring on or after the beginning of the fiscal year of adoption. The Company does not expect that the guidance effective in future periods will have a material impact on our financial statements.

In January 2010, the FASB issued an amendment to ASC 820, "*Fair Value Measurements and Disclosure*," to require reporting entities to separately disclose the amounts and business rationale for significant transfers in and out of Level 1 and Level 2 fair value measurements and separately present information regarding purchase, sale, issuance, and settlement of Level 3 fair value measures on a gross basis. This standard is effective for interim and annual reporting periods beginning after December 15, 2009 with the exception of disclosures regarding the purchase, sale, issuance, and settlement of Level 3 fair value measures which are effective for fiscal years beginning after December 15, 2010. The adoption of this standard is not expected to have a significant impact on the Company's financial statements.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

#### NOTE 3 - Restricted Cash

Restricted cash was an escrow account held by a bank which can only disburse funds to satisfy obligations of the Company owed to clinical research organizations, hospitals, doctors and other vendors and service providers associated with the clinical trials which the Company intends to conduct for its ONCONASE® product. The escrow agreement governing the account terminated April 20, 2011, when all funds had been disbursed from the escrow account.

NOTE 4 - Net Income (Loss) Per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share:

	Three Months Ended	
	October 31,	2010
	2011	
Numerator:		
Net income (loss)	\$1,813,364	\$(8,862,195 )
Denominator:		
Weighted average number of common shares outstanding	49,823,880	47,317,576
Income (Loss) per common share:		
Basic	\$0.04	\$(0.19 )
Diluted	\$0.00	\$(0.19 )
Potentially dilutive securities:		
Warrants	45,833,328	49,784,000
Convertible notes (principal & interest)	23,845,205	22,773,742
Stock options	3,834,267	3,594,867
Total potentially dilutive securities	73,512,800	76,152,609

As the Company has incurred a net loss for the three months ended October 31, 2010, basic and diluted per common share amounts are the same, as the inclusion of all potentially dilutive securities would be anti-dilutive.

NOTE 5 - Property and Equipment

Property and equipment, at cost, consists of the following:

	October	July 31,
	31, 2011	2011
Laboratory equipment	\$276,202	\$276,202
Office equipment	111,049	111,049
Less accumulated depreciation	(381,826)	(379,325)
Property and equipment, net	\$5,425	\$7,926

Depreciation for the three months ended October 31, 2011 and 2010 was \$2,501 and \$11,784, respectively.

NOTE 6 – Accrued Expenses

Accrued expenses consisted of the following:

	October 31, 2011	July 31, 2011
Accrued clinical trial expenses	\$ 193,179	\$ 220,150
Accrued professional fees	252,500	331,390
Accrued compensation expenses	74,423	53,502
Other	12,500	3,359
Total accrued expenses	\$ 532,602	\$ 608,401

NOTE 7 - Convertible Notes and Warrants

On October 19, 2009, the Company completed a sale of 65 units (the “Units”) in a private placement (the “Offering”) to certain investors pursuant to a securities purchase agreement (the “Securities Purchase Agreement”). Each Unit consists of (i) \$50,000 principal amount of 5% Senior Secured Convertible Promissory Notes (collectively, the “Notes”) convertible into shares of the Company’s common stock, par value \$.001 per share (“Common Stock”), (ii) Series A Common Stock Purchase Warrants (the “Series A Warrants”) to purchase in the aggregate that number of shares of Common Stock initially issuable upon conversion of the aggregate amount of Notes issued as part of the Unit, at an exercise price of \$0.15 per share with a three year term and (iii) Series B Common Stock Purchase Warrants (the “Series B Warrants”, together with the Series A Warrants, (the “Warrants”) to purchase in the aggregate that number of shares of Common Stock initially issuable upon conversion of the aggregate amount of Notes issued as part of the Unit, at an exercise price of \$0.25 per share with a five year term. The closing of the Offering occurred on October 19, 2009 (the “Closing”) and the Company received an aggregate of \$3,250,000 in gross proceeds.

At October 31, 2011, the Company accounted for the conversion feature using the fair value method, with the resultant gain recognition recorded in the statement of operations. At October 31, 2011, the fair value of the conversion feature liability was \$0.6 million. The fair value of the conversion feature was \$6.1 million at the closing for the Offering and \$1.3 million at July 31, 2011. The conversion feature was valued at October 31, 2011 and July 31, 2011 using the Black-Scholes valuation model and the following assumptions:

	October 31, 2011	July 31, 2011
Volatility	188.33 %	156.53 %
Risk-free interest rate	0.10 %	0.09 %
Remaining contractual life (years)	0.97	1.22

At the Closing, the Company recorded the Series A and Series B warrants as liabilities at their fair values of \$6.1 million each, based upon the Black-Scholes valuation model. The warrants were accounted for using mark-to-market accounting and charged to the statement of operations in a manner similar to the conversion feature at each reporting date.

At October 31, 2011, the Company accounted for the warrant liabilities using the fair value method, with the resultant gain recognition recorded in the statement of operations. At October 31, 2011, the fair value of the Series A and Series B warrant liabilities were \$0.6 million and \$1.0 million, respectively. The fair value of the Series A warrants was \$6.1 million at the closing for the Offering and \$1.3 million at July 31, 2011. The fair value of the Series B warrant was \$6.1 million at the closing for the Offering and \$2.0 million at July 31, 2011. The Series A and Series B warrant liabilities were valued at October 31, 2011 and July 31, 2011 using the Black-Scholes valuation model and the following assumptions:

Edgar Filing: Tamir Biotechnology, Inc. - Form 10-Q

	Series A Warrants		Series B Warrants	
	<b>October 31, 2011</b>	<b>July 31, 2011</b>	<b>October 31, 2011</b>	<b>July 31, 2011</b>
Volatility	188.33	% 156.53	% 187.10	% 174.80
Risk-free interest rate	0.10	% 0.09	% 0.36	% 0.48
Remaining contractual life (years)	0.97	1.22	2.97	3.22

-13-



NOTE 8 - Stockholders' Equity

During the fiscal year ended July 31, 2011, the Company issued 430,000 stock options to the independent members of its Board of Directors (“BOD”) with an exercise price of \$0.12 per share and a 67 month exercise term. The aggregate grant date fair market value of these options of \$40,850 is being amortized over the seven-month vesting period. The Company recognized compensation expense of \$11,438 for the fiscal year ended July 31, 2011. The Company issued 90,000 stock options to a non-employee consultant for services rendered. The options vested immediately, have an exercise price of \$0.34 per share and a five-year exercise term. The aggregate grant date fair market value of these options, \$25,380, was recognized as an expense by the Company during the fiscal year ended July 31, 2011. During the fiscal year ended July 31, 2011, the Company issued 10,000 shares of its common stock upon the exercise of stock options by an employee at per share exercise prices of \$0.26. The Company realized aggregate gross proceeds of \$2,600 from this exercise.

In April 2011, the Company completed the sale of 2,500,000 shares of its common stock and the issuance of warrants to purchase 2,500,000 common shares pursuant to an agreement with Unilab LP. The Company received proceeds of \$500,000. The warrants have a 5-year term and a purchase price of \$0.50 per share. As of April 2011, the fair value of these warrants was \$0.2 million. The warrants were valued using the Black-Scholes valuation model and the following assumptions:

	April 2011
Volatility	143.73 %
Risk-free interest rate	2.07 %
Remaining contractual life (years)	5.00

These warrants have standard antidilutive provisions; as such, they were classified as equity instruments.

NOTE 9 - Common Stock Warrants

The following table summarizes the activity of common stock warrants issued in connection with the private placements and conversion of notes payable completed in fiscal year 2011 and three months ended October 31, 2011:

	Warrants	Exercise Price	Expiration
Outstanding at July 31, 2010	49,784,000	\$0.15 - \$2.88	7/17/11 to 10/19/14
Expired	(6,450,672 )	2.88	7/17/11
Issued	2,500,000	0.50	4/7/2016
Outstanding at July 31, 2011	45,833,328	\$0.15 - \$2.88	10/19/12 to 4/7/16
Expired	—	—	—
Issued	—	—	—
Outstanding at October 31, 2011	45,833,328	\$0.15-0.50	10/19/12 to 4/7/16
Exercisable at October 31, 2011	45,833,328	\$0.15-2.88	10/19/12 to 4/7/16



NOTE 10 - Stock Options2004 Stock Incentive Plan

The Company's stockholders approved the 2004 Stock Incentive Plan (the "2004 Plan") for the issuance of up to 8,500,000 shares, which provides that common stock and stock options may be granted to employees, directors and consultants. The 2004 Plan provides for the granting of stock options, stock appreciation rights, restricted shares, or other share based awards to eligible employees and directors, as defined in the 2004 Plan. Options granted under the 2004 Plan will have an exercise price equal to the market value of the Company's common stock on the date of the grant. The term, vesting period and time and method of exercise of options granted under the 2004 Plan are fixed by the BOD or a committee thereof.

1997 Stock Option Plan

The Company's stockholders approved the 1997 stock option plan for the issuance of options for up to 2,000,000 shares, which provides that options may be granted to employees, directors and consultants. Options are granted at market value on the date of the grant and generally are exercisable in 20% increments annually over five years starting one year after the date of grant and terminate five years from their initial exercise date. This plan expired in May 2007 except to the extent there are outstanding options.

1993 Stock Option Plan

The Company's stockholders approved the 1993 stock option plan for the issuance of options for up to 3,000,000 shares, which provides that options may be granted to employees, directors and consultants. Options are granted at market value on the date of the grant and generally are exercisable in 20% increments annually over five years starting one year after the date of grant and terminate five years from their initial exercise date. This plan expired in November 2003 except to the extent there are outstanding options.

The fair value of the stock options at the grant date was estimated using the Black-Scholes valuation model and the following assumptions: For post July 31, 2005 grants, the expected term until exercise is derived using the "simplified" method as allowed under the provisions of the SEC's SAB No. 110, "*Disclosures about Fair Value of Financial Instruments*" and represents the period of time that options granted are expected to be outstanding.

Option Activity

The following table summarizes stock option activity for the period July 31, 2011 through October 31, 2011:

	Shares Available for Grant	Options Outstanding	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Balance July 31, 2011	4,705,333	3,854,867	\$ 1.21	5.35	—
Granted	—	—	—	—	—
Cancelled/Expired	—	(20,600 )	0.94	—	—
Exercised	—	—	—	—	—

Edgar Filing: Tamir Biotechnology, Inc. - Form 10-Q

Balance October 31, 2011	4,705,333	3,834,267	1.21	5.12	—
Exercisable at October 31, 2011		2,237,567	\$ 1.14	4.29	

-15-

At April 30, 2011, the Company reversed a total of \$1,318,126 compensation expense related to 1,000,000 performance stock options issued in April 2008. The Company concluded that the performance condition was deemed improbable as of February 2011; therefore, the expense to-date was reversed in accordance to FASB ASC 718, "Compensation – Stock Compensation."

NOTE 11 - Subsequent Events

On December 16, 2011, the Board determined that the employment of Charles Muniz, President, Chief Executive Officer and Chief Financial Officer of Tamir, would end.

On December 23, 2011, the Board appointed Lawrence A. Kenyon as interim Chief Executive Officer and Chief Financial Officer of Tamir, effective immediately. Mr. Kenyon entered into a consulting agreement with the Company pursuant to which he received monthly salary of \$5,000.

On November 23, 2011, Tamir entered into a MOU, with US Pharmacia, hereafter (USPI and/or affiliates), pursuant to which USPI, will be granted the exclusive marketing, sales, and distribution rights of ONCONASE® for use in HPV in the European Territory upon completion of full License payment. Territory includes Western and Eastern Europe. USPI was to pay Tamir the sum of \$1 million in installments provided Tamir achieves certain milestones. Under the MOU, on December 12, 2011, Tamir received an initial payment of \$405,000 and Tamir provided USPI with Proof of Concept demonstrating successful drug formulation of ONCONASE® which will be used to treat genital and skin warts caused by the HPV and *in vivo* penetration of Onconase into the skin. Tamir provided this Proof of Concept by March 31, 2011. USPI has further agreed to make a \$95,000 milestone payment to Tamir, for the completion of a topical formulation and initiation of testing of ONCONASE® in the HPV Proof of Concept study. On June 13, 2012, Tamir received initial results from the independent laboratory performing the ongoing non-clinical Proof of Concept study of ONCONASE® as a potential HPV. Once other pre-clinical milestones are met USPI shall pay Tamir the balance of \$500,000 in installments.

The terms of the License Agreement shall be agreed upon by the parties as outlined in the MOU. Tamir will also be entitled to receive milestone payments based on the achievement of certain regulatory approvals and certain sales goals. In addition, Tamir will receive a royalty on net sales as well as a transfer price for product sold by Tamir to USPI.

Tamir will be responsible for making regulatory filings with and seeking marketing approval of ONCONASE® in the Territory and manufacturing and supplying ONCONASE® to USPI. USPI will be responsible for all commercial activities and related costs in the Territory.

On May 30, 2012, Tamir was served with a complaint filed by its current board member and former President and Chief Executive Officer, Charles Muniz, in the Superior Court of New Jersey, Middlesex County. In the complaint Mr. Muniz alleges that his employment with Tamir was wrongfully terminated and that such termination was in retaliation for his complaints to the Board. Mr. Muniz claims the Board failed to disclose material and significant information to investors and shareholders about ONCONASE® for HPV and that such failure to disclose such information constituted unlawful deception, misrepresentation, violation of the board's fiduciary responsibilities and fraudulent activity. Mr. Muniz is seeking unspecified damages. Tamir believes Mr. Muniz's allegations are without merit and intends to defend itself from his claims to the extent it has the resources to do so.

Although Mr. Muniz's complaint does not specify what information about ONCONASE® for HPV he alleges the Board failed to disclose, based upon communications the Board of Directors has received from Mr. Muniz, Tamir believes that Mr. Muniz is referring to his contention that passive transdermal delivery of large molecular weight molecules was not scientifically possible and that Tamir should not pursue the development of such a formulation of ONCONASE®. Although the preliminary test results discussed above need to be further evaluated through testing, Tamir believes that these preliminary test results demonstrate that Mr. Muniz's contention that passive transdermal delivery of large molecular weight molecules, specifically ONCONASE®, was scientifically impossible, is incorrect. As was explained to Mr. Muniz numerous times before he filed his lawsuit, the Board made a determination to pursue the development of several formulations of ONCONASE® that could achieve passive transdermal delivery, based upon reasonable scientific processes and the emergence of new powerful patented formulations that facilitate transdermal delivery of large molecular weight molecules that might make it possible to develop such a formulation for ONCONASE®. The Board's decision was also based upon the fact that Tamir had essentially no cash remaining, USPI was the company's only funding source and USPI was only willing to fund the development of such a formulation of ONCONASE®. During his tenure as CEO, Mr. Muniz was unable to secure a partner or investors willing to fund any formulation of ONCONASE® for the treatment of HPV other than those formulations that Tamir has pursued.

On October 18, 2012, by action of a majority of the holders (the "Required Holders") of the Tamir Biotechnology, Inc. 5% Senior Secured Convertible Promissory Notes (the "Notes"), the maturity date of the Notes was changed from October 19, 2012 to February 16, 2013 or such earlier date on which demand is made by the Required Holders. No other changes were made to the Notes with this amendment.

On December 14, 2012, completed a private placement of 10 "Units" at a price of \$100,000 per Unit, for aggregate gross consideration of \$1 million (the "Offering"), pursuant to a Securities Purchase Agreement (the "Purchase Agreement") dated as of December 11, 2012. Each Unit consisted of (i) 13,846,945 shares of the Company's common stock, par value \$.001 per share ("Common Stock"), (ii) 1,000 shares of Series A Convertible Preferred Stock of the Company (the "Preferred Shares"), each such Preferred Share being initially convertible into 17,718.52 shares of Common Stock, and (iii) 10-year Common Stock Purchase Warrants (the "Warrants"), to purchase 12,626,184 shares of Common Stock at an exercise price of \$0.003168 per share. Upon completion of Offering, there were issued and outstanding approximately 577,000,000 shares of Common Stock on a fully-diluted basis, of which 315,654,607 (or 70%) were issued in the Offering. The Company's Certificate of Incorporation only authorizes the issuance of 250,000,000 shares of Common Stock. The Preferred Shares issued in the Offering, which are convertible into an aggregate of 177,185,153 shares of Common Stock, will automatically convert into shares of the Common Stock on the date the Company files an amendment to its Certificate of Incorporation increasing the authorized number of shares of Common Stock and/or effecting a reverse stock split so that the Company has a sufficient number of authorized and unissued shares of Common Stock so as to permit the conversion of all outstanding Preferred Shares and all other convertible securities of the Company.

Based on the fact that the Company does not have enough authorized shares, the warrants will be accounted as liability instruments and valued at the fair value and marked to market. As of December 14, 2012 the fair value of the warrants amounted to \$1,261,027.

In connection with the Offering, and as a condition precedent thereto under the Purchase Agreement, the holders of a majority in principal amount (the "Requisite Holders") of the Company's outstanding 5% Senior Secured Convertible Promissory Notes (the "Notes"), entered into a Consent and Waiver (the "Consent") under which (i) the Notes were amended to provide for the automatic conversion of the outstanding principal and interest of all of the Notes upon the election of the Requisite Holders, (ii) the Requisite Holders elected to convert all outstanding principal and interest under the Notes into shares of Common Stock at a price \$0.15 per share (the conversion price under the Notes), and

(iii) the exercise price of the Series B Warrants held by the holders of the Notes were reduced from \$0.25 per share to \$0.01 per share. The fair value of the Series B Warrants amount to \$909,155 at October 31, 2012. The Required Holders consented to the Company's license of Onconase to James O. McCash ("McCash") and/or his affiliates (such licensee being referred to herein as the "Licensee"), on terms which include (i) the issuance to the Licensee of a warrant to purchase 23,750,000 shares of the Company's common stock at an exercise price of \$.01 per share, (ii) no other payments or other consideration provided, or expenditures incurred by, the Company to the Licensee in connection with such License, and (iii) the entry by McCash and affiliated stockholders of the Company into a general release in favor of the Company.

-17-

In connection with the Offering, the Company also entered into a Third Amendment to Investor Rights Agreement (the "Investor Rights Agreement Amendment") with the purchasers of the Units and the Requisite Holders under which the Company has provided registration rights with respect to the Common Stock issued in the Offering and the shares of Common Stock issuable upon conversion of the Preferred Shares and exercise of the Warrants.

On January 3, 2013, Lawrence A. Kenyon notified the BOD that he intends to resign as President, Chief Executive Officer, Chief Financial Officer and Corporate Secretary of the Company as soon as practicable, in order to pursue other interests. Mr. Kenyon remained in his current role until March 31, 2013.

On February 5, 2013, Charles Muniz was removed as a director on the Company's BOD pursuant to an action by written consent of the stockholders constituting over a majority of the outstanding capital stock entitled to vote at an election of directors in accordance with Article II, Section 10 and Article III, Section 14 of the By-Laws. In addition, Fred Knoll, Patrick Ostronic and Ms. Sulley were elected by the requisite stockholders' vote to the Company's BOD to fill the existing vacancies on the BOD and to serve in such positions until the next annual meeting of stockholders or until their earlier removal or resignation. Dr. David Sidransky will remain the Chairman of the BOD of the Company. Fred Knoll is the principal of Knoll Capital and an affiliate of one of the principal stockholders, Europa International, Inc. Patrick Ostronic is affiliated with Unilab LP, another principal stockholder.

On January 25, 2013, the SEC has commenced an administrative proceeding against the Company alleging that the Company is delinquent in filing its periodic filings with the SEC since the Company has not filed any of its periodic reports since the quarterly report on Form 10-Q filed for the period ended January 31, 2011. The purpose of the hearing is to determine whether it is appropriate for the SEC to suspend for a period of up to 12 months or to permanently revoke the registration of the Company's common stock pursuant to Section 12 of the Securities Exchange Act of 1934. This action was instituted concurrently with a temporary suspension of trading of the common stock ordered by the SEC from January 25, 2013 through February 7, 2013. The Company has responded to SEC motion and is attempting to become current. The Company has filed its two delinquent Form 10-Ks for the years ending July 31, 2012 and 2011 and is in the processes of filings its delinquent Form 10-Qs.



## ITEM 2 . MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The information contained in this Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended July 31, 2011 and presume readers have access to, and will have read, the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.*

*The following discussion contains certain statements that may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, "Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in our Annual Report on Form 10-K for the year ended July 31, 2011 in the section entitled "Risk Factors" for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited financial statements and notes thereto that appear elsewhere in this report.*

### **Overview**

We are a biopharmaceutical company primarily engaged in the discovery and development of a new class of antiviral therapeutic drugs for the treatment of pathological conditions. Our proprietary drug discovery and development program consists of novel therapeutics which are being developed from amphibian ribonucleases ("RNases").

Since our inception in 1981, we have devoted the vast majority of our resources to the research and development of ONCONASE<sup>®</sup>, as well as other related drug candidates. In recent years we have focused our resources towards the completion of the clinical program for ONCONASE<sup>®</sup> in patients suffering from unresectable malignant mesothelioma ("UMM").

On February 4, 2011, we decided to suspend the Phase II trial of ONCONASE<sup>®</sup> in combination with carboplatinum regimens in patients suffering from non-small cell lung cancer who have reached maximum progression after receiving two cycles of Alimta plus Carboplatin. Given our limited resources and based upon previously reported positive *in vitro* results, we shifted our focus to the completion of *in vivo* studies for Cytomegalovirus ("CMV") and

human papillomavirus (“HPV”).

We have incurred losses since inception and we have not received the Food and Drug Administration (“FDA”) approval of any of our drug candidates. We expect to continue to incur losses for the foreseeable future as we continue our efforts to receive marketing approval for our drug candidates, which includes the sponsorship of human clinical trials. Until we are able to consistently generate sufficient revenue through the sale of drug or non-drug products, we anticipate we will be required to fund the development of our pre-clinical compounds and drug product candidates primarily by other means, including, but not limited to, licensing the development or marketing rights to some of our drug candidates to third parties, collaborating with third parties to develop our drug candidates, or selling Company issued securities.

-19-

### **Critical Accounting Policies and Estimates**

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. On an ongoing basis, we evaluate our estimates which are based on historical experience and on other assumptions that we believe to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions. The discussion of Critical Accounting Policies is incorporated herein by reference from Company's annual report on to Form 10-K for the fiscal 2012. There have been no significant changes in the critical accounting policies since year-end.

### **Results of Operations**

#### **For the Three Months Ended October 31, 2011 and 2010**

##### *Research and Development Expenses*

Research and development expense was \$70,571 and \$219,326 for the three months ended October 31, 2011 and 2010, respectively.

##### *General and Administrative Expenses*

General and administrative expenses were \$122,937 and \$409,770 for the three months ended October 31, 2011 and 2010, respectively. This decrease was due to lower costs associated with being public, as the Company did not file all quarterly and the year-end annual report, as well as reduced compensation expense and other general office expenses due to our reduced operations.

##### *Other Income and Expense*

Other income (expense) was \$2,006,872 and \$(8,233,099) for the three months ended October 31, 2011 and 2010, respectively. This increase was directly due to increased income from the market-to-market valuation of the derivative liability.

**Liquidity and Capital Resources**

Net cash used in operating activities was \$207,735 and \$242,745 in the three months ended October 31, 2011 and 2010, respectively.

Net cash used in financing activities was \$0 and \$1,658 in the three months ended October 31, 2011 and 2010, respectively.

The Company suffered recurring losses from operations and has an accumulated deficit of \$107,161,649 at October 31, 2011.

In April 2011, the Company completed the sale of 2,500,000 shares of its common stock and the issuance of warrants to purchase 2,500,000 common shares pursuant to an agreement with Unilab LP. The Company received proceeds of \$500,000. The warrants have a 5-year term and a purchase price of \$0.50 per share.

On December 14, 2012, the Company completed a private placement of 10 Units at a price of \$100,000 per Unit, for aggregate gross consideration of \$1 million pursuant to the Purchase Agreement. Each Unit consisted of (i) 13,846,945 shares of Common Stock, (ii) 1,000 Preferred Shares, each such Preferred Share being initially convertible into 17,718.52 shares of Common Stock, and (iii) Warrants to purchase 12,626,184 shares of Common Stock at an exercise price of \$0.003168 per share.

-20-

In connection with the Offering, and as a condition precedent thereto under the Purchase Agreement, the Requisite Holders of the Company's outstanding Notes, entered into a Consent and Waiver under which (i) the Notes were amended to provide for the automatic conversion of the outstanding principal and interest of all of the Notes upon the election of the Requisite Holders, (ii) the Requisite Holders elected to convert all outstanding principal and interest under the Notes, in the aggregate amount of \$3,891,838, into shares of Common Stock at a price \$0.15 per share (the conversion price under the Notes), and (iii) the exercise price of the Series B Warrants held by the holders of the Notes were reduced from \$0.25 per share to \$0.01 per share.

The Company has financed its operations since inception primarily through the sale of our equity securities and convertible debentures in registered offerings and private placements. Additionally, we have raised capital through other debt financings, the sale of our state tax benefit and research products. Because our business does not generate positive cash flow from operating activities, the Company will need to raise additional capital in order to fully commercialize our product or to fund development efforts relating to additional indications. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Based upon the reduced operations, we currently believe that our cash reserves can support our activities through July 2013. We may seek to satisfy future funding requirements through public or private offerings of securities or with collaborative or other arrangements with corporate partners. Additional financing or strategic transactions may not be available when needed or on terms acceptable to us, if at all. If adequate financing is not available, we may be required to delay, scale back, or eliminate certain of our research and development programs, relinquish rights to certain of our technologies, drugs or products, or license third parties to commercialize products or technologies that we would otherwise seek to develop ourselves.

### **Inflation and Seasonality**

Inflation and seasonality have not been material to us during the past five years.

### **Recent Accounting Pronouncements**

In January, 2010, the FASB issued Accounting Standards Update (ASU) No. 2010-06, "*Improving Disclosure about Fair Value Measurements.*" ASU 2010-06 added new requirements for disclosures into and out of Levels 1 and 2 fair value measurements and information on purchases, sales, issuances and settlements on a gross basis in the reconciliation of Level 3 fair value measurements. It also clarifies existing fair value disclosures about the level of disaggregation, inputs and valuation techniques. The guidance in ASU 2010-06 is effective for annual and interim reporting periods in fiscal years beginning after November 15, 2010. We do not anticipate the adoption of the new guidance to have any effect on our financial statements or results of operations.

Refer to the notes to the financial statements in our Annual Form 10-K for the year ending July 31, 2010 for a complete description of recent accounting standards which we have not yet been required to implement and may be applicable to our operation, as well as those significant accounting standards that have been adopted during the current year.

**Off-Balance Sheet Arrangements**

As of October 31, 2011, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

As a “smaller reporting company” as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item 3.

### **ITEM 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules, regulations and related forms, and that such information is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of October 31, 2011, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and our principal financial officer of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report due to the limited size of our staff and budget.

## **PART II - OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

On October 1, 2010, Robert Love, a former Chief Financial Officer of the Company, filed an amended complaint in *Love v. Alfacell Corp. et al.*, Case No. 3:09-cv-05199-MLC-LHG (the “Amended Complaint”), against the Company and certain of its current and former directors in the U.S. District Court, District of New Jersey, asserting violations of federal and state securities laws, direct and derivative common law claims for fraud and breach of fiduciary duty, a direct claim for negligent misrepresentation and derivative claims for gross negligence and corporate waste in connection with the Company’s Phase IIIb clinical trial for ONCONASE®. On March 8, 2012, the Company settled for \$50,000.

On February 23, 2012, the Company settled an action with Pharmatech Oncology, Inc. (“Pharmatech”) whereby the Company agreed to use Pharmatech if the Company conducts any oncology clinical trial using ONCONASE®. Additionally, the Company agreed to pay Pharmatech \$200,000 in consideration of entering into the settlement.

On May 15, 2012, Charles Muniz, the Company’s former President, Chief Executive Officer and Chief Financial Officer and a former director of the Company, filed a complaint against the Company asserting that he had been wrongfully discharged by the Company in violation of federal and state laws. More specifically, the complaint alleged the Company terminated Mr. Muniz’s employment and position as an executive officer of the Company in retaliation of Mr. Muniz’s complaints regarding the Company’s failure to disclose material information in reports filed with the SEC. The complaint seeks unspecified compensatory and punitive damages. The Company believes that the claims are meritless and intends to defend the case vigorously.

On July 26, 2012, certain investors and stockholders of the Company who own more than 7,500,000 shares of the Company’s common stock filed a complaint against the Company and certain current and former executive officers and directors of the Company alleging fraud and breaches of fiduciary duty. The complaint asserts that the Company and the other defendants failed to properly pursue the Company’s application with the FDA for approval of its therapeutics. The complaint alleges that the Company and the other defendants committed securities fraud by failing to disclose material information in reports filed with the SEC in violation of federal and state securities laws. The complaint also alleges that the executive offices and directors of the Company breached their fiduciary duties to the Company’s stockholders by failing to take corrective action and by failing to accurately disclose material information to the Company’s stockholders. In addition to direct claims made by the plaintiffs, the complaint asserts derivative claims for fraud and breaches of fiduciary obligations on behalf of all stockholders of the Company. The complaint seeks over \$7,000,000 in compensatory damages and an unspecified amount in punitive damages. The Company believes the claims are baseless and intends to defend the case vigorously.



On January 25, 2013, the SEC commenced an administrative proceeding against the Company alleging the Company is delinquent in filing its periodic filings with the SEC since the Company has not filed any of its periodic reports since the quarterly report on Form 10-Q filed for the period ended January 31, 2011. The purpose of the hearing is to determine whether it is appropriate for the SEC to suspend for a period of up to 12 months or to permanently revoke the registration of the Company's common stock pursuant to Section 12 of the Securities Exchange Act of 1934. This action was instituted concurrently with a temporary suspension of trading of the common stock ordered by the SEC from January 25 through February 7, 2013. The Company responded to the SEC motion and is attempting to become current. On April 25, 2013, the Company filed its two delinquent Form 10-Ks for the years ended July 31, 2012 and 2011 and is in the processes of filing its delinquent Form 10-Qs.

#### **ITEM 1A. RISK FACTORS**

In addition to the other risk factors and information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2011, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K is not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, operating results and/or cash flows.

#### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES**

None.

#### **ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

#### **ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

None.

#### **ITEM 5. OTHER INFORMATION**

None.

#### **ITEM 6. EXHIBITS**

**Exhibit Description**

- 31.1 Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14 and 15d-14 as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14 and 15d-14 as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 32 Certification of the Company's Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

-23-

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TAMIR BIOTECHNOLOGY, INC.**

Date: May 6, 2013 By: /s/ Jamie Sulley  
Jamie Sulley  
President  
(Principal Executive Officer)

Date: May 6, 2013 By: /s/ Joanne Barsa  
Joanne Barsa  
Chief Financial Officer and Secretary  
(Principal Financial Officer and Chief Accounting Officer)

